3 imperatives to drive the EHR of the future

By Melissa Honour, VP, Product Management | February 22, 2021

When it comes to advancing EHR design to create a better experience for both providers and patients, there are three key drivers that are the basis for every decision we make. Read More

Tags: Provider Experience, Insights, Corporate


Why I’m with Ontada: The power of research

By Michelle Myers, VP, Life Sciences Partnerships | February 19, 2021

Michelle Myers shares a personal and moving story about why she is proud to work at Ontada. Read More

Tags: Patient Journey


Ontada’s Clear Value Plus Provides 800,000th Chemotherapy Treatment Decision

February 18, 2021

Most used oncology pathway technology solution enables evidence-based decisions and accelerates prior authorization, resulting in smarter, quicker patient treatment. Read More

Tags: Corporate, Press Releases


Pragmatic Trials Offer Benefits in the Development of Precision Medicine for Lung Cancer

February 14, 2021

MYLUNG, a new real-world research study, seeks to understand the barriers and opportunities of using biomarker testing for non-small cell lung cancer. Read More

Tags:


MYLUNG Study Launches, Aiming to Advance Use of Precision Medicine for Metastatic Non-Small Cell Lung Cancer Patients

February 04, 2021

McKesson, a global leader in healthcare committed to transforming cancer research, has joined together with life sciences companies, oncology providers and patient advocacy groups in a unique collaborative effort, titled MYLUNG, to advance precision medicine options for non-small cell lung cancer (NSCLC) patients who are being treated in the community. Read More

Tags: Corporate


Overcoming the Challenges of Biomarker Testing

January 17, 2021

Driven by innovations in precision medicine, advances in cancer treatment over the past decade have been significant. As costs continue to drop for molecular analysis, comprehensive biomarker testing will play an increasingly important role in the understanding of cancer and its treatment. Read More

Tags: Provider Experience, In the News


How Real-World Data is Helping Speed Oncology Drug Development

December 11, 2020

Sarah Alwardt, Vice President of Operations at Ontada, describes how historical patient information can be used in current and future clinical trials, often eliminating the need for new trial participants. She also introduces us to Ontada, a new McKesson business that uses technology, real-world data, and research capabilities as a way to accelerate innovation and improve cancer therapies. Read More

Tags:


Amgen and McKesson Launch Strategic Agreement to Advance Cancer Innovation in Communities

December 04, 2020

Enhanced agreement to transform cancer care, improve outcomes by accelerating development and access to life-changing medicines Read More

Tags: Corporate


Meet Ontada

By Giancarlo Brutocao, VP, Marketing | December 03, 2020

Introducing Ontada, the latest effort in the fight against cancer. Learn how partnering with the largest oncology network & leveraging real-world evidence sets us apart Read More

Tags: Leadership, Insights, Corporate


McKesson Launches Ontada, an Oncology Technology and Insights Business Dedicated to Help Advance Cancer Research and Care

December 03, 2020

McKesson Corporation today announced the launch of Ontada, an oncology technology and insights business designed to support innovation, acceleration, and evidence generation to drive better outcomes for patients with cancer.  Read More

Tags: Leadership, Corporate, Press Releases


How to Leverage Real-World Data as COVID-19 Transforms Clinical Trials

By Targeted Oncology | October 27, 2020

Due to efforts to reduce exposure to the coronavirus, oncology patient volumes initially decreased, treatment regimens were disrupted or altered, and new cancer diagnoses also slowed. This affected not only patient care, but also clinical trials. Read More

Tags: In the News


Optimizing Benefit in Targeted Therapies Requires Multipronged Educational Approach

By Targeted Oncology | October 25, 2020

Much is still unknown about the cancer process and how targeted therapies work on specific tumor vulnerabilities. Providers must closely follow evolving information, especially regarding adverse events Read More

Tags: Provider Experience, Corporate, In the News


Using Real-World Data to Understand the Impact of COVID-19 on Oncology Patient Care

By Targeted Oncology | September 18, 2020

When the coronavirus disease 2019 (COVID-19) pandemic and stay-at-home orders swept across the country in March, oncology care—like nearly every aspect of the US health care system—was dramatically affected. Read More

Tags: Corporate, Patient Journey, In the News


Cancer Care in the COVID-19 World: Adjusting to a New Reality

By The Cancer Letter | July 31, 2020

Oncology practices face difficult challenges while delivering care in the middle of COVID-19, as they care for patients who are at higher risk for this potentially deadly disease. While there is still much to learn about how COVID-19 impacts various patient populations, early studies of COVID-19 patients with a history of cancer provide some insight. Read More

Tags: Provider Experience, Corporate, In the News


Ad Campaign Says Don’t Let COVID-19 Fear Delay Doctor Visits

By Wall Street Journal | July 07, 2020

Several large health-care organizations are partnering on an advertising campaign to encourage people to return to their medical providers as the pandemic continues, a sign of how difficult it has been to allay fears of catching the coronavirus during visits to a doctor or pharmacy. Read More

Tags: Corporate, Patient Journey, In the News


McKesson Appoints Lyn Fitzgerald as Vice President of Sales for McKesson Data, Evidence & Insights

By McKesson | May 05, 2020

McKesson announced today that Lyn Fitzgerald has joined as Vice President of Sales for McKesson Data, Evidence & Insights, the company’s market-leading oncology data business that uses real-world data and real-world evidence to accelerate the development of breakthrough oncology treatments. Read More

Tags: Leadership, Corporate, Press Releases


Real-World Evidence Should be Part of Clinical Trials in Oncology

By OncLive | March 28, 2020

As cancer treatment shifts from broad chemotherapy to highly personalized therapies, drug development in oncology is also evolving. There are currently some 71,000 oncology trials listed on ClinicalTrials.gov, with new studies being added every day. Although the trials may involve varied forms of disease or new modalities such as cell and gene therapies, all share 1 thing in common: They are competing with one another to recruit patients. Read More

Tags: Corporate, Clinical Development, In the News


US Oncology Research Announces Schedule of Presentations at the 2019 American Society of Hematology Annual Meeting and Exposition

By McKesson | December 05, 2019

During the 61st American Society of Hematology (ASH) Annual Meeting and Exposition, principal investigators from The US Oncology Network (The Network) and US Oncology Research will demonstrate detailed results from more than 20 studies covering topics including lymphoma, multiple myeloma, leukemia and more. Read More

Tags: Corporate, Clinical Development, Press Releases


Learning to Harmonize: Ten Health Care Research Organizations Tell Us How They Formulated Common Definitions for Real-World Endpoints

By The Cancer Letter | November 22, 2019

Leadership of 10 companies share their visions of the future of data sharing, describe their portfolios in real-world evidence, and opine on what it would take to convince FDA accept real-world endpoints in regulatory decision-making in oncology. Read More

Tags: Corporate, Clinical Development, In the News


Real-World Evidence at a Glance: How a Collaboration of “Frenemies” Produced Common Definitions for Real-World Endpoints

By The Cancer Letter | November 22, 2019

Ten health care research organizations, with help from FDA and NCI, have developed a set of common definitions for real-world endpoints, including overall survival, progression-free survival, and other non-traditional endpoints. The new common definitions are published as part of a pilot study led by Friends of Cancer Research, which announced the conclusions of this phase of the project at a recent gathering in Washington, D.C. Read More

Tags: Corporate, Clinical Development, In the News


Real-World Data, Evidence Should be Leveraged in Clinical Research to Better Include and Ultimately Treat Larger Patient Populations

By The Cancer Letter | October 18, 2019

The growth of personalized medicine in oncology continues to fuel a shift from traditional chemotherapies to immunotherapy. Currently, there are more than 30 immunotherapies approved for use in the United States, with more than 2,300 immunotherapy clinical trials listed on ClinicalTrials.gov. Read More

Tags: Corporate, Clinical Development, In the News


McKesson and Aetion Collaborate to Advance Cancer Research with Real-World Data

By McKesson | October 15, 2019

Today Aetion and McKesson announced a strategic collaboration focused on advancing the use of real-world evidence (RWE) in cancer research to benefit patients, regulators, the biopharma industry and payers. The partnership will provide best-in-class solutions in multiple tumor types, including breast, lung and melanoma cancers. Read More

Tags: Corporate, Clinical Development, Press Releases


McKesson Playing Pivotal Role in Phase II of Friends of Cancer Research Real-World Evidence Initiative

By McKesson | August 08, 2019

McKesson is pleased to announce that it is participating in Phase II of the Friends of Cancer Research (Friends) Real-World Evidence (RWE) pilot project to advance the understanding and inform future uses of RWE. Read More

Tags: Corporate, Clinical Development, Press Releases


Dr. Nicholas Robert Discusses How Real-World Data Can Complement Clinical Trial Data

By American Journal of Managed Care | July 16, 2019

With real-world data, there's an opportunity to take a new agent and see how patients outside that clinical trial would do, explained Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences. Read More

Tags: Corporate, Clinical Development, In the News


Dr. Nicholas Robert Explains the Benefits, Challenges of Using RWE for Measuring Clinical End Points

By American Journal of Managed Care | May 23, 2019

Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses the benefits of real-world evidence (RWE) for measuring end points, as well as the challenges posed by variability in clinical practice. Read More

Tags: Corporate, Clinical Development, In the News


How Pharma Can Help Ease the Growing Burden on Healthcare Professionals

By PM 360 | May 16, 2019

Reaching, engaging, and educating physicians is often a pharma marketer’s main task. After all, physicians are the ones who make the decisions on which brands to prescribe—or at least they used to be. As more physicians become part of larger networks, accountable care organizations (ACOs), or integrated delivery networks (IDNs), they are starting to lose some of their prescribing power. Read More

Tags: Provider Experience, Corporate, In the News


Implementing RWE to Advance Innovative Medicine

By Applied Clinical Trials | May 10, 2019

Drug development in oncology continues to evolve. Sarah Alwardt, VP of Data, Evidence, and Insight Operations for McKesson, discusses the shift to highly personalized therapies, including new modalities like cell and gene therapies. Read More

Tags: Corporate, Clinical Development, In the News


Rethinking the Use of Real-World Evidence to Improve Policy Decisions

By American Journal of Managed Care | April 19, 2019

Randomized controlled trials (RCT) remain the gold standard for evaluating the safety and efficacy of drugs before making them available to patients. However, drug development is increasingly shifting towards specialty medications with narrow indications and smaller patient populations. Under these conditions, clinical trials may not be able to recruit enough patients and can take too long to complete. Read More

Tags: Corporate, Clinical Development, In the News


The Scrutiny on Rebates and Prices will Change the Pharma Payer Relationship

By PM 360 | April 15, 2019

The government is the largest payer in the U.S. through Medicare and Medicaid, and the current administration has made no secret that they aren’t happy about the high prices of drugs. This isn’t a particularly new issue for elected officials, but it is one both sides of the aisle actually agree on and they are making sure people know they want changes Read More

Tags: Corporate, Patient Access, In the News


AI Will Converge with Physician-Directed Care

By OncLive | January 05, 2019

Improvements and greater familiarity with artificial intelligence will lead to systems of checks and balances that will create trust and fulfill the promise of computer-assisted precision medicine. Read More

Tags: Provider Experience, Corporate, In the News


FDA Framework Signals Openness to Real-World Evidence for Drug Approvals

By Pharmacy Practice News | December 13, 2018

The FDA has signaled that it will take a much more welcoming approach to the use of real-world data (RWD) and real-world evidence (RWE) in decision making regarding the approval of new drugs and biologics, with the release of a new framework for the regulatory use of such evidence. Read More

Tags: Corporate, Clinical Development, In the News


Real-World Evidence (RWE): Advancing Both Clinical and Commercial Objectives

By Pharmaceutical Commerce | November 08, 2018

The widening scope of RWE data available from patients is changing both clinical and post-approval practices for drug development. Read More

Tags: Corporate, Clinical Development, In the News


Current and Potential Significance of Real-World Data in Value-Based Outcomes, Compliance

By Journal of Clinical Pathways | September 24, 2018

Journal of Clinical Pathways spoke with Sarah Alwardt, PhD, vice president, health informatics and health economics and outcomes research operations, McKesson, to highlight the key talking points on real-world data in value-based outcomes and compliance for her upcoming presentation at the Value-Based Oncology Management conference. Read More

Tags: Corporate, Patient Access, In the News


Beyond Big Data: Meeting the Specialty Marketing Challenge

By Pharmaceutical Executive | September 14, 2018

With specialty companies getting smarter in applying their big data insights to product marketing, the true commercial potential of machine learning and predictive modeling may soon be within reach. Read More

Tags: Corporate, Patient Access, In the News


MCC Rx Marks First Use of Real-World Data for FDA Approval

By Clinical Oncology News | September 13, 2018

In April 2017, the FDA approved the first-ever drug treatment for the rare and aggressive skin cancer Merkel cell carcinoma (MCC). The immunotherapy drug avelumab (Bavencio, EMD Serono/Pfizer) was approved based on the results of a multicenter, open-label, phase 2 trial as well as data from a real-world retrospective analysis of patients with metastatic MCC treated with chemotherapy. Read More

Tags: Corporate, Clinical Development, In the News


Challenges with Treating Merkel Cell Carcinoma and Other Rare Diseases

By American Journal of Managed Care | July 01, 2018

In an interview with Rare Disease Report®, Nicholas J. Robert, MD, of McKesson Specialty Health, discussed the challenges and advances involving treating with treating Merkel cell carcinoma. Read More

Tags: Corporate, Patient Journey, In the News


Real-World Evidence from McKesson Supports First-Ever FDA Approval for Metastatic Merkel Cell Carcinoma Drug

By McKesson | March 16, 2018

A powerful, real-world evidence study designed by McKesson for its biopharma partner played a key role in the Food and Drug Administration’s (FDA) approval for first-line indication for a rare disease. Read More

Tags: Corporate, Clinical Development, Press Releases